Sign in
Taking people in United StatesNo phase

Xeomin Injections for Migraine in Traumatic Brain Injury and Anomalous Health Incidents

Compares Xeomin injections for migraine in adults with brain injury or anomalous health incidents.

Key facts

Who runs it
Uniformed Services University of the Health Sciences
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
Status
Recruiting
People taking part
60 people, planned
Started
5 Aug 2025
Expected to end
6 Jun 2028
Type of study
Observational, 2 groups
Treatments tested
  • Xeomin (incobotulinumtoxinA)
Record updated
5 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who work for the US Government, or whose adult family member does. They must have had Xeomin injections to prevent migraine linked to a head injury (TBI) or an anomalous health incident (AHI).

Age
18 years or older
Sex
All sexes can join.
Disease stage
Migraine related to traumatic brain injury (TBI) or anomalous health incidents (AHI).
Earlier treatment
Must have received Xeomin treatment to prevent migraine at a Military Treatment Facility or another US medical facility.

Main reasons for not taking part

  • Prisoners
  • People who cannot give informed consent because of impaired decision-making
  • People who are not US citizens
  • Dual nationals of the country where they are currently located

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • At least 18 years of age
  • Able to provide written consent in English
  • An employee of the US Government, or an adult family member of a US Government employee
  • Have received Xeomin treatment to prevent migraine related to TBI or AHI at a Military Treatment Facility or other US Medical Facility
  • Able to participate in at least 80% of the assessments
  • A US Citizen and not a dual national of the country where you are currently located

Who cannot take part

  • Prisoner
  • Decisionally impaired and unable to provide informed consent
  • Non-US citizen

Where in United States

  • National Intrepid Center of Excellence (NICOE)Bethesda, United StatesContact: David L Brody, MD, PhDTaking people

About the trial

What the trial wants to find out

This cohort study aims to compare the efficacy of Xeomin injections for migraine management in patients with a history of Traumatic Brain Injury (TBI) versus those with a history of Anomalous Health Incidents (AHI). The study will be conducted at the National Intrepid Center of Excellence (NICOE) in Bethesda, MD. The primary objective is to determine if Xeomin injections result in different outcomes for migraine management between TBI and AHI patients. This is a combined retrospective and prospective cohort study design. Patients scheduled for Xeomin treatments will be categorized into TBI and AHI groups. For the prospective cohort, participants will complete a baseline questionnaire, receive their scheduled Xeomin treatment, and participate in follow-up interviews at 4-6 weeks and 10-12 weeks post-treatment. For the retrospective cohort, similar information will be acquired from existing records. Statistical analysis will compare migraine characteristics and treatment responses between the two groups. All data will be de-identified to protect patient privacy.

The 2 groups in the trial

  • TBI Cohort

    Patients with a history of Traumatic Brain Injury (TBI) receiving Xeomin treatments for migraine management. The anticipated number of participants is 40.

    Treatment: Xeomin (incobotulinumtoxinA)

  • AHI Cohort

    Patients with a history of Anomalous Health Incidents (AHI) receiving Xeomin treatments for migraine management. The anticipated number of participants is 20.

    Treatment: Xeomin (incobotulinumtoxinA)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Efficacy of Xeomin as a Prophylactic Therapy for Migraine in Patients With Traumatic Brain Injuries (TBIs) Versus Anomalous Health Incidents (AHIs)
Plain-language title
Xeomin Injections for Migraine in Traumatic Brain Injury and Anomalous Health IncidentsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 December 2025